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Philanthotoxin analogues
Philanthotoxins, a group of non-competitive antagonists of ionotropic receptors, are
composed of long-chain polyamines connected to a relatively nonpolar head-group via an
amide bond. The interest in medicinal chemistry and pharmacology of philanthotoxins has
recently been highlighted by the observation that specificity of their antagonist action on
various classes of ionotropic receptors can be achieved by modification of the polyamine
portion of the molecule. Thus, natural and synthetic toxins (1) are known to antagonise
various types of nicotinic acetylcholine receptors (nAChRs) and ionotrophic glutamate
receptors (iGluRs) with similar potency. On the other hand, analogues in which the secondary
amino groups are replaced by methylene groups or oxygen atoms (2) exhibit enhanced
antagonist activity at mammalian muscle-type nAChR and Torpedo nAChR, while being
inactive on several types of iGluR. Previous structure-activity investigations on synthetic
analogues containing a symmetrical spermine moiety, or closely related polyamine which have
been tested on iGluR and nAChR, emphasise the importance of the hydrophobic character of
the headgroup. In contrast, no information about the influence of the structure of the
headgroup on the potency of philanthotoxin analogues that lack inner basic sites is available.
In an effort to produce Structure Activity Relationships in such series, a library of compounds
was synthesised testing whether compounds lacking the inner basic sites bind to nAChR in a
similar fashion (Solid-phase synthesis and biological evaluation of a combinatorial library of
philanthotoxin analogues, J.W. Jaroszewski et. al., J. Med. Chem., 43, (2000), 4526-4533). A
library of 18 individual compounds was synthesised on trityl chloride solid phase. Of those
compounds tested which lacked the inner basic sites, all were inactive when tested on rat brain
non-NMDA receptors. The success of this library protocol lies in the increase in understanding
of SAR of antagonism of nAChR by philanthotoxin analogies lacking inner basic sites.
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Urokinase inhibitors
Urokinase-type plasminogen activator (u-PA) is one of the two major endogenous
plasminogen activators that catalyse the conversion of the zymogen plasminogen to the
fibrinolytic protease plasmin. The primary role of u-PA is to generate plasmin in events
involving the degradation of the extracellular matrix. Localisation of u-PA on the cell surface
is achieved by binding to urokinase plasminogen activator receptor (u-PAR), which is attached
to the cell membrane via its glycosyl phosphatidyl inositol (GPI) anchor. Recent advances in
the elucidation of the function of the u-PA/u-PAR system have led to an increased
understanding of the role played by this enzyme in angiogenesis, cell invasion and cancer
metastasis. Efforts are focused on the development of selective direct and mechanism-based
synthetic u-PA inhibitors as potential therapeutic targets for cancer, arthritis and pathological
angiopathies (Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors, T.G.
Nolan et. al., Bioorg. Med. Chem. Lett., 10, (2000), 983-987). A library of eleven peptidyl
argininals were synthesised in solution. One of the most potent compounds isolated was 3
which possessed an IC50 of 23.1 nM against human urokinase enzyme, with 63 fold selectivity
against human plasamin enzyme and >100-fold selectivity against human t-PA enzyme. This
work has provided further delineation of the active site requirements of urokinase plasminogen
activator and in the discovery of potent and selective inhibitors.
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